IP Library › Granted Patent US 12,304,928
Granted Patent B2
US 12,304,928 · App. 17/053,230 · Granted May 20, 2025

Epitope restriction for antibody selection

Inventors: Payton Weidenbacher (Stanford, CA); Peter S. Kim (Stanford, CA)
Assignees: CZ Biohub SF, LLC; The Board of Trustees of the Leland Stanford Junior University
C07K14/005A61K39/00C07K1/1072C07K16/1018C07K16/1063C07K2317/35C12N2740/16122C12N2760/16122
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,304,928
App. No.
17/053,230
Granted
May 20, 2025
Kind
B2
Abstract

Provided are methods of producing antigenic proteins and antigenic protein complexes and compositions and vaccines produced from such methods. Also provided are methods of immunizing a subject using such compositions and vaccines. The antigenic proteins and protein complexes of this disclosure are useful as vaccine immunogens that can direct the immune system of a subject immunized with such vaccine immunogens to generate antibodies against a specific region, or epitope, of a protein that is known to be productive or neutralizing in the case of an infection. Also provided are methods of screening for B cells expressing antibodies that bind specifically to a particular, desired epitope (target region). Compositions and kits comprising one or more antigenic protein, protein complexes, binding partners, and polynucleotides encoding any thereof, are also described.

Claims (18)

1. A method of making a modified hemagglutinin influenza virus protein, or a fragment or a variant thereof, the method comprising the steps of:

(a) providing a hemagglutinin influenza virus protein, or the fragment or the variant thereof, comprising a target region comprising an epitope of interest and a non-target region;

(b) providing a binding partner, wherein the binding partner binds specifically to the target region;

(c) contacting the hemagglutinin influenza virus protein, or the fragment or the variant thereof, with the binding partner under conditions in which the binding partner binds specifically to the target region, thereby forming a protein complex comprising the hemagglutinin influenza virus protein, or the fragment or the variant thereof, and the binding partner;

(d) contacting amino acid residues of the hemagglutinin influenza virus protein, or the fragment or the variant thereof, in the protein complex with a modifying reagent under conditions sufficient to form the modified hemagglutinin influenza virus protein, or the fragment or the variant thereof, thereby forming the modified hemagglutinin influenza virus protein, or the fragment or the variant thereof, in the protein complex, wherein each of a plurality of amino acid residues in the non-target region of the hemagglutinin influenza virus protein, or the fragment or the variant thereof, have a modifying component covalently attached thereto, and wherein amino acid residues of the target region of the hemagglutinin influenza virus protein, or the fragment or the variant thereof, do not have the modifying component attached thereto; and

(e) separating the modified hemagglutinin influenza virus protein, or the fragment or the variant thereof, from the binding partner in the protein complex, thereby providing the modified hemagglutinin influenza virus protein, or the fragment or the variant thereof, with reduced or ablated immunogenicity of the non-target region.

2. The method of claim 1 , wherein in step (c) the binding partner or the hemagglutinin influenza virus protein, or the fragment or the variant thereof, is attached to a solid support.

3. The method of claim 1 , wherein step (d) comprises reacting the protein complex with the modifying reagent and a coupling reagent under conditions sufficient to form the modified hemagglutinin influenza virus protein, or the fragment or the variant thereof.

4. The method of claim 1 , wherein the modifying component is a polyethylene glycol polymer, a glycopolymer (polysaccharide), a polysialic acid, a hyaluronic acid, a peptide, a protein, a polynucleotide, or a combination of any thereof.

5. The method of claim 1 , wherein the binding partner comprises at least one of a protein, a peptide, an aptamer, a chemical ligand, a lectin, or a combination of any thereof.

6. The method of claim 5 , wherein the binding partner comprises at least one of an antibody or a receptor.

7. The method of claim 6 , wherein the binding partner is a recombinant multivalent antibody.

8. The method of claim 1 , wherein the target region is conserved across at least one of influenza A viruses, influenza B viruses, or influenza C viruses.

9. The method of claim 1 , wherein the influenza virus hemagglutinin protein, or the fragment or the variant thereof, comprises a head region and a stem region, wherein the head region is the non-target region, and the target region comprises the stem region or a portion thereof.

10. The method of claim 1 , wherein the influenza virus hemagglutinin protein, or the fragment or the variant thereof, comprises a head region that comprises a hemagglutinin receptor binding site, wherein the hemagglutinin receptor binding site is the target region.

11. The method of claim 1 , wherein the influenza virus hemagglutinin protein, or the fragment or the variant thereof, is a hemagglutinin protein fragment, or a variant thereof, comprising a stem region and lacking, or substantially lacking all, of a head region.

12. The method of claim 1 , wherein the influenza virus hemagglutinin protein, or the fragment or the variant thereof, comprises at least one amino acid substitution in the non-target region, wherein the at least one amino acid substitution incorporates at least one non-native amino acid residue that increases or decreases affinity of the binding partner to the non-target region.

13. The method of claim 1 , wherein the influenza virus hemagglutinin protein, or the fragment or the variant thereof, comprises at least one amino acid substitution in the non-target region, wherein the at least one amino acid substitution incorporates at least one non-native amino acid residue to which the modifying reagent is attachable.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2021
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: CHAN ZUCKERBERG BIOHUB, INC.; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 056257/0816 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2020
From: WEIDENBACHER, PAYTON; KIM, PETER S.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 054302/0310 →
Continuity (4)
Provisional Application 62780595 · Dec 17, 2018
Provisional Application 62688939 · Jun 22, 2018
Provisional Application 62673617 · May 18, 2018
Related Publication 20210139542A1 · May 13, 2021
References Cited (47)
US 9441019B2 · Nabel et al. · 2016 [cited by applicant]
US 20100092505A1 · Bianchi et al. · 2010 [cited by applicant]
WO 2010045321A2 · 2010 [cited by applicant]
WO 2013043729A1 · 2013 [cited by applicant]
WO 2013044203A2 · 2013 [cited by applicant]
WO 2016205704A1 · 2016 [cited by applicant]
WO 2016205704A2 · 2016 [cited by applicant]
Medina et al. “Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses,” Sci Transl Med, May 29, 2013, Pagegs. 1-23, vol. 5. [cited by applicant]
Weidenbacher et al. “Protect, modify, deprotect (PMD): Astrategy for creating vaccines to elicit antibodies targeting a specificepitope,” Proc Natl Acad Sci USA, Apr. 29, 2019, pp. 9947-9952, vol. 116, No. 20. [cited by applicant]
International Search Report, Application No. PCT/US2019/032945, Aug. 12, 2019, 4 pages. [cited by applicant]
Written Opinion, Application No. PCT/US2019/032945, Aug. 12, 2019, 6 pages. [cited by applicant]
Burton et al., “Broadly Neutralizing Anti bodies to HIV and Their Rolein Vaccine Design”, Annu. Rev. Immunol., 2016, pp. 635-659, (34). [cited by applicant]
Bergström et al., “Epitope Specific Suppression of IgG Responses by Passively Administered Specific IgG: Evidence of Epitope Masking”, Front. Immunol., Mar. 6, 2017, pp. 1-12. [cited by applicant]
McClements et al., “Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease”, Proc. Natl. Acad. S… [cited by applicant]
Lutz et al., “Unmodified mRNA in LNPs constitutes a competitive technologyfor prophylactic vaccines”, NPJ Vaccines, Oct. 19, 2017, pp. 1-9, (2), Article No. 29. [cited by applicant]
Konigsberg et al., “The development of IL-2 conjugated liposomes for therapeutic purposes”, Biochimica et Biophysica Acta (BBA)—Biomembranes, Mar. 13, 1998, pp. 243-251, vol. 1370, Issue 2. [cited by applicant]
Benacerraf et al., “Studies on Hypersensitivity—I. Delayed and Arthus-type Skin Reactivity to Protein Conjugates in Guinea Pigs”, Immunology. Jan. 1959, pp. 53-63, 2(1). [cited by applicant]
Jardine et al., “Rational HIVimmunogen design to target specific germline B cell receptors”, Science, May 10, 2013, pp. 711-716, 340 (6133). [cited by applicant]
Salmaso et al., “Preparation and characterization of active site protected poly (ethylene glycol)-avidin bioconjugates”, Biochim. Biophys. Acta-Gen. Subj. Oct. 30, 2005, pp. 57-66, vol. 1726, Issue 1. (https://www.scien… [cited by applicant]
Uhr et al., “Regulatory Effect of Antibody onthe Immune Response”, Adv. Immunol. 1968, vol. 8, pp. 81-127. [cited by applicant]
Moller., Studies on the Mechanism of immuno logical enhancement of tumor homografts. I. Specificity of Immunologic Enhancement:, JNCI30, Jun. 1963, vol. 30, Issue 6, pp. 1153-1175. [cited by applicant]
Kanekiyo et al., “Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing HIN1 antibodies”, Nature , May 22, 2013, 499(7456), pp. 102-106. [cited by applicant]
Sutton et al., “Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines”, NPJ Vaccines, Dec. 15, 2017, vol. 2, Article 35, pp. 1-11. [cited by applicant]
Impagliazzo et al., “A stable trimeric influenza hemagglutinin stemas a broadly protective immunogen”, Science, Sep. 18, 2015, 349(6254), pp. 1301-1306. [cited by applicant]
Lee et al., “Design and Structure of an Engineered Disulfide-Stabilized Influenza Virus Hemagglutinin Trimer”,J. of Virology, Apr. 29, 2015, 89(14) , pp. 7417-7420. [cited by applicant]
Mallajosyula et al., “Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype”, Front. Immunol., Jun. 26, 2015, vol. 6, Article 329, pp. 1-12. [cited by applicant]
Yassine et al., “Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection”, Nature Medicine, 2015 (21), pp. 1065-1070. [cited by applicant]
Jardine et al., “Rational HIV Immunogen Designto Target Specific Germline B Cell Receptors”, Science, May 10, 2013, 340(6133) , pp. 711-716. [cited by applicant]
McGuire et al., Diverse Recombinant HIV-1 Envs Fail To Activate B Cells Expressing the Germline B Cell Receptors of the Broadly Neutralizing Anti-HIV-1 Antibodies PG9 and 447-52D, J. of Virology, Mar. 2014, 88(5), pp. 2… [cited by applicant]
Sanders et al., “A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp 140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies”, PLoS Pathology, Sep. 19, 2013, 9(9… [cited by applicant]
Georgiev et al., “Single-Chain Soluble BG505.SOSIP gp 140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env”, 2015, J. of Virology 89(10):5318-5329. [cited by applicant]
Kwon et al., “Crystalstructure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env”, Nature Struct. Mol. Biol., Jun. 22, 2015, 22(7), pp. 522-531. [cited by applicant]
Chuang et al., “Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity”, J. Virol., May 2017, 91(10), pp. 1-18. [cited by applicant]
Joyce et al., “Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains”, Cell Reports, Dec. 5, 2017, vol. 21, Issue 10, pp. 2992-3002. [cited by applicant]
Rutten et al., “A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers”, Cell Reports, Apr. 10, 2018, vol. 23, Issue 2, pp. 584-595. [cited by applicant]
McLellan et al., “Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncy tial Virus”, Science, Nov. 1, 2013, 342(6158), pp. 592-598. [cited by applicant]
Finn, “Bacterialpolysaccharide-protein conjugate vaccines”, British Medical Bulletin, Jan. 1, 2004, vol. 70, Issue 1, pp. 1-14. [cited by applicant]
Kadam & Wilson, “A small-molecule fragment that emulates binding of receptor and broadly neutralizing antibodies to influenza A hemagglutinin”, Proc. Natl. Acad. Sci. U.S.A., 2018, 115(16): 1-6. [cited by applicant]
Bernard & Francis (2014). “Chemical strategies for the covalent modification of filamentous phage”, Front. Microbiol. Dec. 23, 2014, 5:734, pp. 1-7. [cited by applicant]
Gilmore et al., “N-terminal protein modification through a biomimetic transamination reaction”, Angew. Chem. Int. Ed. Engl., Aug. 11, 2006, vol. 45, Issue 32, pp. 5307-5311. [cited by applicant]
Liu & Schultz, “Adding new chemistries to the genetic code”, Annu. Rev. Biochem. 2010, vol. 79, pp. 413-444. [cited by applicant]
Berge et al., “Pharmaceutical Salts”, [cited by applicant]
McClements, “Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animalmodels of herpes simplexvirus-2 disease”, Proc. Natl. Acad. Sci. USA, … [cited by applicant]
Lutz et al., “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines”, NPJ Vaccines, Oct. 19, 2017, vol. 2, Art. 29, pp. 1-9. [cited by applicant]
Whittle et al., “Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages”, J Virol., Apr. 2014, 88(8), pp. 4047-4057. [cited by applicant]
Han et al., “A long noncoding RNA protects the heart from pathological hypertrophy”, Nature, Aug. 10, 2014, vol. 514, Issue 7520, pp. 102-106. [cited by applicant]
Doud et al., Accurate Measurement of the Effects of All Amino-Acid Mutations on Influenza Hemagglutinin, Viruses, Jun. 3, 2016, 8(6):155, pp. 1-17. [cited by applicant]